The Safety of Dapoxetine/Tadalafil Combination Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03177746
Recruitment Status : Recruiting
First Posted : June 6, 2017
Last Update Posted : June 14, 2018
Information provided by (Responsible Party):
Neutec Ar-Ge San ve Tic A.Ş

May 23, 2017
June 6, 2017
June 14, 2018
September 14, 2017
November 14, 2018   (Final data collection date for primary outcome measure)
Evaluation of safety of study drug [ Time Frame: 4 weeks ]
Number of Participants with Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment
Same as current
Complete list of historical versions of study NCT03177746 on Archive Site
  • Evaluation of change in Intra-vaginal Ejaculation Latency Time (IELT) compared to baseline [ Time Frame: 4 weeks ]
    Intra-vaginal ejaculation latency time difference of one minute or more will be considered as efficient.
  • Evaluation of IIEF-15 (International Index of Erectile Function) score compared to baseline [ Time Frame: 4 weeks ]
    Increase in IIEF score will be considered as efficacy.
  • Evaluation of premature ejaculation symptom scores compared to baseline [ Time Frame: 4 weeks ]
    Increase in IIEF scores will be considered as efficacy.
Same as current
Not Provided
Not Provided
The Safety of Dapoxetine/Tadalafil Combination Therapy
The Safety of Dapoxetine/Tadalafil Combination Therapy in Treatment of Men With Premature Ejaculation and Erectile Dysfunction
The purpose of this study is to evaluate the safety and efficacy of Dapoxetine/Tadalafil 30/20 mg film-coated tablet in the treatment of men with premature ejaculation and erectile dysfunction.
Not Provided
Phase 4
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Premature Ejaculation
  • Erectile Dysfunction
  • Safety Issues
Drug: Dapoxetine/Tadalafil 30/20 mg film coated tablet

During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.

Study drug should not be used more than 1 tablet every 24 hours during the treatment.

Other Name: Tada Plus
Experimental: Dapoxetine/Tadalafil 30/20 mg film coated tablet
Intervention: Drug: Dapoxetine/Tadalafil 30/20 mg film coated tablet
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
March 14, 2019
November 14, 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18-64 years old men,
  • Participants must be heterosexual males and in a stable monogamous sexual relationship with a female partner for at least 6 months and will continue throughout the study,
  • Clinical diagnosis of erectile dysfunction, IIEF score ≤21,
  • Premature Ejaculation Diagnostic Tool (PEDT) score must be ≥11
  • Patients with life-long PE and acquired PE according to the description of International Society for Sexual Medicine (ISSM) ,
  • The patient and his partner must have sexual intercourse twice a week for the duration of the study,
  • Commitment to comply with the study protocol,
  • Patients who sign informed consent form (ICF).

Exclusion Criteria:

  • History of medical events such as surgical interventions or neurologic conditions (e.g., multiple sclerosis), trauma, or infections that are associated with the development of symptoms of premature ejaculation (PE) and considered a potential cause of PE,
  • Having genital abnormalities, except penile curvature unless not prevent sexual intercourse,
  • Developed erectile dysfunction or premature ejaculation due to drug use or quit taking drugs,
  • Any conditions that prevent sexual intercourse with partners
  • History of epilepsy,
  • Severe renal insufficiency,
  • Liver disease,
  • History of in last 6 months stroke, myocard infarction, cardiac insufficiency (New York Cardiovascular Associates (NYCA) phase II-IV), atrioventricular block or message disorder such as sick sinus syndrome, severe ischemic cardiac disease, syncope, unstable angina, life-threatening arrhythmia or hypotension,
  • Non-Arteritic Anterior ischemic optic neuropathy,
  • Patients who are not eligible to have sexual intercourse due to existing health problems,
  • Autonomic neuropathy, retinitis pigmentosa, blood diseases, active peptic ulcer, abnormalities in ECG, severe systemic disease that cannot be controlled,
  • Systolic/Diastolic blood pressure at rest <90/50 mmHg and 170/100 mmHg<
  • History of allergy to Selective Serotonin Reuptake Inhibitor (SSRI) and phosphodiesterase inhibitor drugs,
  • Continuing to use or quitted in last 3 months of Monoamine oxidase inhibitor (MAOI), Thioridazine, Serotonin Reuptake Inhibitor (SSRI), Selective-norepinephrine Reuptake Inhibitor (SNRI), Serotonergic drug/herbal product, tricyclic antidepressant and atypical antipsychotic drugs,
  • Use of nitrates, alfa blockers, vasodilators, ketoconazole, itraconazole, ritonavir, saquinavir, telithromycin, nefazodone, nelfinavir, atazanavir, cimetidine, erythromycin, clarithromycin, fluconazole, amprenavir, fosamprenavir, aprepitant, verapamil, diltiazem, any kind of vasodilator, antiplatelet, anticoagulant, dapoxetine, phosphodiesterase 5 inhibitor, alcohol and stimulant drug,
  • Patients on a different therapy (behavioral therapy or other drugs that are applied locally) for PE treatment
  • During the study, the possibility of taking medication which may affect the study drug's pharmacokinetic/pharmacodynamic properties
  • Patients who are defining symptoms of prostatitis clinically
  • Thyroid hormone disorders
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Gender Eligibility Description: Since drug is indicated in men, study population will consist of men.
18 Years to 64 Years   (Adult)
Contact: Neutec R&D 00902128505102 ext 0000
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Undecided
Neutec Ar-Ge San ve Tic A.Ş
Neutec Ar-Ge San ve Tic A.Ş
Not Provided
Not Provided
Neutec Ar-Ge San ve Tic A.Ş
June 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP